A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab

Berger Martin D.; Stintzing Sebastian; Heinemann Volker; Cao Shu; Yang Dongyun; Sunakawa Yu; Matsusaka Satoshi; Ning Yan; Okazaki Satoshi; Miyamoto Yuji; Suenaga Mitsukuni; Schirripa Marta; Hanna Diana L.; Soni Shivani; Puccini Alberto; Zhang Wu; Cremolini Chiara; Falcone Alfredo; Loupakis Fotios; Lenz Heinz-Josef

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab

【24h】

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab

机译：维生素D转运蛋白基因内的多态性预测了用Folfiri / Bevacizumab或Folfiri / Cetuximab治疗的转移结直肠癌患者的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Vitamin D exerts its inhibitory influence on colon cancer growth by inhibiting Wnt signaling and angiogenesis. We hypothesized that SNPs in genes involved in vitamin D transport, metabolism, and signaling are associated with outcome in metastatic colorectal cancer (mCRC) patients treated with first-line FOLFIRI and bevacizumab.

机译：目的：维生素D通过抑制WNT信号传导和血管生成来施加其对结肠癌生长的抑制作用。我们假设参与维生素D传输，代谢和信号传导中涉及的基因中的SNP与用一线Folfiri和Bevacizumab治疗的转移性结肠直肠癌（MCRC）患者的结果相关。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2018年第4期|共10页
作者
Berger Martin D.; Stintzing Sebastian; Heinemann Volker; Cao Shu; Yang Dongyun; Sunakawa Yu; Matsusaka Satoshi; Ning Yan; Okazaki Satoshi; Miyamoto Yuji; Suenaga Mitsukuni; Schirripa Marta; Hanna Diana L.; Soni Shivani; Puccini Alberto; Zhang Wu; Cremolini Chiara; Falcone Alfredo; Loupakis Fotios; Lenz Heinz-Josef;
展开▼
作者单位

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Dept Prevent Med Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Dept Prevent Med Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

Azienda Osped Univ Pisana Ist Toscano Tumori UO Oncol Med Pisa Italy;

Azienda Osped Univ Pisana Ist Toscano Tumori UO Oncol Med Pisa Italy;

IRCCS Ist Oncol Veneto Oncol Med 1 Padua Italy;

Univ Southern Calif Keck Sch Med Norris Comprehens Canc Ctr Div Med Oncol Los Angeles CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab [J] . Berger Martin D., Stintzing Sebastian, Heinemann Volker, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第4期

机译：维生素D转运蛋白基因内的多态性预测了用Folfiri / Bevacizumab或Folfiri / Cetuximab治疗的转移结直肠癌患者的结果
2. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab [J] . Pharmacogenomics . 2015,第18期

机译：VEGFA多态性对FOLFIRI-西妥昔单抗治疗转移性结直肠癌患者临床结局的重要影响
3. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 [J] . PietrantonioF., GarassinoM.C., TorriV., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第10期

机译：答复德国AIO随机研究KRK-0306中FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者一线治疗的KRAS突变肿瘤患者亚组分析
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Evaluating response to treatment and predicting outcome in patients with metastatic colorectal carcinoma using statistical learning theory . [D] . Margolis, Daniel Eli. 2010

机译：运用统计学习理论评价转移性大肠癌患者的治疗反应和预测结局。
6. Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES a Bevacizumab Observational Cohort Study [O] . Johanna C. Bendell, Tanios S. Bekaii-Saab, Allen L. Cohn, 2012

机译：最初用FOLFOX-贝伐单抗或FOLFIRI-贝伐单抗治疗的转移性结直肠癌患者的治疗模式和临床结果：贝伐单抗观察性队列研究的ARIES结果
7. PCN66 A Cost and Outcomes Analysis of Bevacizumab plus Folfiri Versus Cetuximab Plus Folfiri for the Treatment of First-Line Metastatic Colorrectal Cancer Patients from the Brazilian Private Payer Perspective [O] . R. Caponero, E.A.V. Santos, C.T. Buschinelli, 2011

机译：PCN66贝伐单抗Plus Folfiri对Cetuximab Plus Folfiri的成本和结果分析，用于从巴西私人付款人的临时术语治疗一线转移性菌血病患者

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab

摘要

著录项

相似文献

相关主题

期刊订阅